In the News | Friends of Cancer Research

You are here

In the News

March 15, 2019
President Donald Trump has proposed to cut $4.7 billion from the NIH budget, with almost $900 million coming out of NCI during the fiscal year 2020.   According to the White House’s proposal, “A... Read more
March 14, 2019
The newly named acting commissioner of the Food and Drug Administration (FDA) is poised to take over at a crucial time for the agency, as outgoing Commissioner Scott Gottlieb leaves an ambitious... Read more
March 13, 2019
As part of a push to transform clinical trial eligibility criteria that have been accepted over time without a clear scientific or clinical rationale, the FDA on Tuesday published four draft guidance... Read more
March 13, 2019
Health and Human Services (HHS) Secretary Alex Azar wasted little time in naming a new leader for FDA. Norman (Ned) Sharpless, director of the National Cancer Institute (NCI) at the National... Read more
March 13, 2019
The presence of comorbid conditions was associated with lower rates of clinical trial discussions between patients and their physicians, subsequently leading to decreased trial participation,... Read more
March 12, 2019
Friends of Cancer Research Applauds This Appointment The Secretary of Health and Human Services (HHS) Alex M. Azar III has appointed Dr. Norman E. Sharpless to be the acting Commissioner of the U.S.... Read more
March 12, 2019
U.S. President Donald Trump’s administration has tapped National Cancer Institute Director Norman Sharpless to serve as acting commissioner for the Food and Drug Administration, following the... Read more
March 12, 2019
Executive Summary Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.   The US FDA's incoming acting commissioner shares an... Read more
March 12, 2019
National Cancer Institute Director Ned Sharpless will become acting commissioner of FDA when current Commissioner Scott Gottlieb resigns in early April, HHS Secretary Alex Azar announced at a House... Read more
March 12, 2019
Executive Summary Genentech/AbbVie drug becomes the seventh product known to be pilot-testing US FDA's new pathway; our infographic details the program's goals and how it has been used so far for... Read more

Pages